1. Centers for Disease Control and Prevention (CDC). Hepatitis Surveillance: CDC2000 Contract No.: 57, 2000.

2. Centers for Disease Control and Prevention (CDC). Viral Hepatitis Statistics and Surveillance. Available at: http://www.cdc.gov/hepatitis/Statistics/index.htm.

3. BellBP, Kruszon‐MoranD, ShapiroCN, et al.Hepatitis A virus infection in the United States: serologic results from the Third National Health and Nutrition Examination Survey. Vaccine2005;23:5798. CrossRef

4. Centers for Disease Control and Prevention (CDC). Viral Hepatitis Statistics and Surveillance. Available at: http://www.cdc.gov/hepatitis/Statistics/2013Surveillance/Commentary.htm#hepC.

5. VogtTM, WiseME, BellBP, et al.Declining hepatitis A mortality in the United States during the era of hepatitis A vaccination. J Infect Dis2008;197:1282. CrossRef

6. MathiesenLR, MollerAM, PurcellRH, et al.Hepatitis A virus in the liver and intestine of marmosets after oral inoculation. Infect Immun1980;28:45.

7. CohenJI, FeinstoneS, PurcellRH. Hepatitis A virus infection in a chimpanzee: duration of viremia and detection of virus in saliva and throat swabs. J Infect Dis1989;160:887. CrossRef

8. BowerWA, NainanOV, HanX, et al.Duration of viremia in hepatitis A virus infection. J Infect Dis2000;182:12. CrossRef

9. YotsuyanagiH, IinoS, KoikeK, et al.Duration of viremia in human hepatitis A viral infection as determined by polymerase chain reaction. J Med Virol1993;40:35. CrossRef

10. FujiwaraK, YokosukaO, EhataT, et al.Frequent detection of hepatitis A viral RNA in serum during the early convalescent phase of acute hepatitis A. Hepatology1997;26:1634. CrossRef

11. NobleRC, KaneMA, ReevesSA, et al.Posttransfusion hepatitis A in a neonatal intensive care unit. JAMA1984;252:2711. CrossRef

12. MannucciPM, GdovinS, GringeriA, et al.Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group. Ann Intern Med1994;120:1. CrossRef

13. GrindeB, Stene‐JohansenK, SharmaB, et al.Characterisation of an epidemic of hepatitis A virus involving intravenous drug abusers–infection by needle sharing?J Med Virol1997;53:69. CrossRef

14. CoreyL, HolmesKK. Sexual transmission of hepatitis A in homosexual men: incidence and mechanism. N Engl J Med1980;302:435. CrossRef

15. Centers for Disease Control (CDC). Hepatitis A among homosexual men–United States, Canada, and Australia. MMWR Morb Mortal Wkly Rep1992;41:155, 61.

16. GoodmanRA, CarderCC, AllenJR, et al.Nosocomial hepatitis A transmission by an adult patient with diarrhea. Am J Med1982;73:220. CrossRef

17. BellBP, ShapiroCN, AlterMJ, et al.The diverse patterns of hepatitis A epidemiology in the United States‐implications for vaccination strategies. J Infect Dis1998;178:1579. CrossRef

18. SmithPF, GrabauJC, WerzbergerA, et al.The role of young children in a community‐wide outbreak of hepatitis A. Epidemiol Infect1997;118:243. CrossRef

19. DesenclosJC, KlontzKC, WilderMH, et al.A multistate outbreak of hepatitis A caused by the consumption of raw oysters. Am J Public Health1991;81:1268. CrossRef

20. O′MahonyMC, GoochCD, SmythDA, et al.Epidemic hepatitis A from cockles. Lancet1983;1:518.

21. DentingerCM, BowerWA, NainanOV, et al.An outbreak of hepatitis A associated with green onions. J Infect Dis2001;183:1273. CrossRef

22. WheelerC, VogtTM, ArmstrongGL, et al.An outbreak of hepatitis A associated with green onions. N Engl J Med2005;353:890. CrossRef

23. RosenblumLS, MirkinIR, AllenDT, et al.A multifocal outbreak of hepatitis A traced to commercially distributed lettuce. Am J Public Health1990;80:1075. CrossRef

24. HutinYJ, PoolV, CramerEH, et al.A multistate, foodborne outbreak of hepatitis A. National Hepatitis A Investigation Team. N Engl J Med1999;340:595. CrossRef

25. KaneM. Global programme for control of hepatitis B infection. Vaccine1995;13(Suppl 1):S47. CrossRef

26. WeinbaumCM, WilliamsI, MastEE, et al.Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep2008;57(RR–8):1.

27. TroisiCL, HollingerFB, HootsWK, et al.A multicenter study of viral hepatitis in a United States hemophilic population. Blood1993;81:412.

28. ChangMH. Hepatitis B: long‐term outcome and benefits from mass vaccination in children. Acta Gastroenterol Belg1998;61:210.

29. LivingstonSE, SimonettiJP, BulkowLR, et al.Clearance of hepatitis B e antigen in patients with chronic hepatitis B and genotypes A, B, C, D, and F. Gastroenterology2007;133:1452. CrossRef

30. BothaJF, RitchieMJ, DusheikoGM, et al.Hepatitis B virus carrier state in black children in Ovamboland: role of perinatal and horizontal infection. Lancet1984;1:1210. CrossRef

31. AlterMJ, HadlerSC, MargolisHS, et al.The changing epidemiology of hepatitis B in the United States. Need for alternative vaccination strategies. JAMA1990;263:1218. CrossRef

32. Hepatitis C–global prevalence (update). Wkly Epidemiol Rec2000;75:18.

33. Global surveillance and control of hepatitis C.J Viral Hepat1999;6:35. CrossRef

34. FrankC, MohamedMK, StricklandGT, et al.The role of parenteral antischistosomal therapy in the spread of hepatitis C virus in Egypt. Lancet2000;355:887. CrossRef

35. DarwishMA, RaoufTA, RushdyP, et al.Risk factors associated with a high seroprevalence of hepatitis C virus infection in Egyptian blood donors. Am J Trop Med Hyg1993;49:440.

36. TanakaE, KiyosawaK, SodeyamaT, et al.Prevalence of antibody to hepatitis C virus in Japanese schoolchildren: comparison with adult blood donors. Am J Trop Med Hyg1992;46:460.

37. DennistonMM, JilesRB, DrobeniucJ, et al.Chronic hepatitis C virus infection in the United States, National Health and Nutrition Examination Survey 2003 to 2010.Ann Intern Med2014;160:293. CrossRef

38. BrettlerDB, AlterHJ, DienstagJL, et al.Prevalence of hepatitis C virus antibody in a cohort of hemophilia patients. Blood1990;76:254.

39. MakrisM, PrestonFE, TrigerDR, et al.Hepatitis C antibody and chronic liver disease in haemophilia. Lancet1990;335:1117. CrossRef

40. ZouS, DorseyKA, NotariEP, et al.Prevalence, incidence, and residual risk of human immunodeficiency virus and hepatitis C virus infections among United States blood donors since the introduction of nucleic acid testing. Transfusion2010;50:1495. CrossRef

41. Conry‐CantilenaC, VanRadenM, GibbleJ, et al.Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med1996;334:1691. CrossRef

42. AlterMJ, Kruszon‐MoranD, NainanOV, et al.The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med1999;341:556. CrossRef

43. AlterMJ, HadlerSC, JudsonFN, et al.Risk factors for acute non‐A, non‐B hepatitis in the United States and association with hepatitis C virus infection. JAMA1990;264:2231. CrossRef

44. BrestersD, Mauser‐BunschotenEP, ReesinkHW, et al.Sexual transmission of hepatitis C virus. Lancet1993;342:210. CrossRef

45. AkahaneY, KojimaM, SugaiY, et al.Hepatitis C virus infection in spouses of patients with type C chronic liver disease. Ann Intern Med1994;120:748. CrossRef

46. TerraultNA, DodgeJL, MurphyEL, et al.Sexual transmission of hepatitis C virus among monogamous heterosexual couples: The HCV partners study. Hepatology2013;57:881. CrossRef

47. TerraultNA. Sexual activity as a risk factor for hepatitis C. Hepatology2002;36(5 Suppl 1):S99. CrossRef

48. DantaM, BrownD, BhaganiS, et al.Recent epidemic of acute hepatitis C virus in HIV‐positive men who have sex with men linked to high‐risk sexual behaviours. AIDS2007;21:983. CrossRef

49. FrederickT, BurianP, TerraultN, et al.Factors associated with prevalent hepatitis C infection among HIV‐infected women with no reported history of injection drug use: the Women's Interagency HIV Study (WIHS). AIDS Patient Care STDS2009;23:915. CrossRef

50. ThomasSL, NewellML, PeckhamCS, et al.A review of hepatitis C virus (HCV) vertical transmission: risks of transmission to infants born to mothers with and without HCV viraemia or human immunodeficiency virus infection. Int J Epidemiol1998;27:108. CrossRef

51. ZanettiAR, TanziE, PaccagniniS, et al.Mother‐to‐infant transmission of hepatitis C virus. Lombardy Study Group on Vertical HCV Transmission. Lancet1995;345:289. CrossRef

52. LinHH, KaoJH, HsuHY, et al.Possible role of high‐titer maternal viremia in perinatal transmission of hepatitis C virus. J Infect Dis1994;169:638. CrossRef

53. OhtoH, TerazawaS, SasakiN, et al.Transmission of hepatitis C virus from mothers to infants. The Vertical Transmission of Hepatitis C Virus Collaborative Study Group. N Engl J Med1994;330:744. CrossRef

54. GibbDM, GoodallRL, DunnDT, et al.Mother‐to‐child transmission of hepatitis C virus: evidence for preventable peripartum transmission. Lancet2000;356:904. CrossRef

55. LinHH, KaoJH, HsuHY, et al.Absence of infection in breast‐fed infants born to hepatitis C virus‐infected mothers. J Pediatr1995;126:589. CrossRef

56. NakashimaK, IkematsuH, HayashiJ, et al.Intrafamilial transmission of hepatitis‐C virus among the population of an endemic area of Japan. JAMA1995;274:1459. CrossRef

57. AllanderT, GruberA, NaghaviM, et al.Frequent patient‐to‐patient transmission of hepatitis C virus in a haematology ward. Lancet1995;345:603. CrossRef

58. AbaciogluYH, BacaksizF, BaharIH, et al.Molecular evidence of nosocomial transmission of hepatitis C virus in a haemodialysis unit. Eur J Clin Microbiol Infect Dis2000;19:182. CrossRef

59. ThompsonND, PerzJF, MoormanAC, et al.Nonhospital health care‐associated hepatitis B and C virus transmission: United States, 1998‐2008. Ann Intern Med2009;150:33. CrossRef

60. EstebanJI, GomezJ, MartellM, et al.Transmission of hepatitis C virus by a cardiac surgeon. N Engl J Med1996;334:555. CrossRef

61. BronowickiJP, VenardV, BotteC, et al.Patient‐to‐patient transmission of hepatitis C virus during colonoscopy. N Engl J Med1997;337:237. CrossRef

62. SchvarczR, JohanssonB, NystromB, et al.Nosocomial transmission of hepatitis C virus. Infection1997;25:74. CrossRef

63. RossRS, ViazovS, GrossT, et al.Transmission of hepatitis C virus from a patient to an anesthesiology assistant to five patients. N Engl J Med2000;343:1851. CrossRef

64. RizzettoM, PonzettoA, ForzaniI. Hepatitis delta virus as a global health problem. Vaccine1990;8(Suppl):S10, discussion S21. CrossRef

65. FarciP. Delta hepatitis: an update. J Hepatol2003;39(Suppl 1):S212. CrossRef

66. WeisfuseIB, HadlerSC, FieldsHA, et al.Delta hepatitis in homosexual men in the United States. Hepatology1989;9:872. CrossRef

67. RosinaF, ConoscitoreP, CupponeR, et al.Changing pattern of chronic hepatitis D in Southern Europe. Gastroenterology1999;117:161. CrossRef

68. GaetaGB, StroffoliniT, ChiaramonteM, et al.Chronic hepatitis D: a vanishing Disease? An Italian multicenter study. Hepatology2000;32:824. CrossRef

69. WongDC, PurcellRH, SreenivasanMA, et al.Epidemic and endemic hepatitis in India: evidence for a non‐A, non‐B hepatitis virus aetiology. Lancet1980;2:876. CrossRef

70. DasK, AgarwalA, AndrewR, et al.Role of hepatitis E and other hepatotropic virus in aetiology of sporadic acute viral hepatitis: a hospital based study from urban Delhi. Eur J Epidemiol2000;16:937. CrossRef

71. KhurooMS. Study of an epidemic of non‐A, non‐B hepatitis. Possibility of another human hepatitis virus distinct from post‐transfusion non‐A, non‐B type. Am J Med1980;68:818. CrossRef

72. NaikSR, AggarwalR, SalunkePN, et al.A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull World Health Organ1992;70:597.

73. KuniholmMH, PurcellRH, McQuillanGM, et al.Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988‐1994. J Infect Dis2009;200:48. CrossRef

74. KhurooMS, KamiliS, JameelS. Vertical transmission of hepatitis E virus. Lancet1995;345:1025. CrossRef

75. Kabrane‐LaziziY, FineJB, ElmJ, et al.Evidence for widespread infection of wild rats with hepatitis E virus in the United States. Am J Trop Med Hyg1999;61:331.

76. MengXJ, DeaS, EngleRE, et al.Prevalence of antibodies to the hepatitis E virus in pigs from countries where hepatitis E is common or is rare in the human population. J Med Virol1999;59:297. CrossRef

77. ClaysonET, InnisBL, MyintKS, et al.Detection of hepatitis E virus infections among domestic swine in the Kathmandu Valley of Nepal. Am J Trop Med Hyg1995;53:228.

78. WeitzM, BaroudyBM, MaloyWL, et al.Detection of a genome‐linked protein (VPg) of hepatitis A virus and its comparison with other picornaviral VPgs. J Virol1986;60:124.

79. CohenJI, TicehurstJR, PurcellRH, et al.Complete nucleotide sequence of wild‐type hepatitis A virus: comparison with different strains of hepatitis A virus and other picornaviruses. J Virol1987;61:50.

80. BrownEA, DaySP, JansenRW, et al.The 5′ nontranslated region of hepatitis A virus: secondary structure and elements required for translation in vitro. J Virol1991;65:5828.

81. BrownEA, ZajacAJ, LemonSM. In vitro characterization of an internal ribosomal entry site (IRES) present within the 5′ nontranslated region of hepatitis A virus RNA: comparison with the IRES of encephalomyocarditis virus. J Virol1994;68:1066.

82. CohenJI, RosenblumB, FeinstoneSM, et al.Attenuation and cell culture adaptation of hepatitis A virus (HAV): a genetic analysis with HAV cDNA. J Virol1989;63:5364.

83. AllaireM, ChernaiaMM, MalcolmBA, et al.Picornaviral 3C cysteine proteinases have a fold similar to chymotrypsin‐like serine proteinases. Nature1994;369:72. CrossRef

84. WolstenholmeAJ, CoatesJP, DouglassW. Expression of hepatitis A virus poly(U) polymerase in the periplasmic space of Escherichia coli. J Gen Virol1993;74:531. CrossRef

85. RueckertRR. Picornaviridae: the viruses and their replication. In: FieldsBN, KnipeDM, HowleyPM, et al. (eds). Fields Virology. Philadelphia: Lippincott‐Raven; 1996: 609.

86. KaplanG, TotsukaA, ThompsonP, et al.Identification of a surface glycoprotein on African green monkey kidney cells as a receptor for hepatitis A virus. EMBO J1996;15:4282.

87. WheelerCM, FieldsHA, SchableCA, et al.Adsorption, purification, and growth characteristics of hepatitis A virus strain HAS‐15 propagated in fetal rhesus monkey kidney cells. J Clin Microbiol1986;23:434.

88. ShimizuYK, MathiesenLR, LorenzD, et al.Localization of hepatitis A antigen in liver tissue by peroxidase‐conjugated antibody method: light and electron microscopic studies. J Immunol1978;121:1671.

89. MagniusLO, NorderH. Subtypes, genotypes and molecular epidemiology of the hepatitis B virus as reflected by sequence variability of the S‐gene. Intervirology1995;38:24.

90. StuyverL, De GendtS, Van GeytC, et al.A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness. J Gen Virol2000;81:67. CrossRef

91. DaneDS, CameronCH, BriggsM. Virus‐like particles in serum of patients with Australia‐antigen‐associated hepatitis. Lancet1970;1:695. CrossRef

92. GavilanesF, Gonzales‐RosA, PetersonD. Structure of hepatitis B surface antigen: characterization of the lipid components and their association with the viral proteins. J Biol Chem1982;257:7770.

93. RadziwillG, ZentgrafH, SchallerH, et al.The duck hepatitis B virus DNA polymerase is tightly associated with the viral core structure and unable to switch to an exogenous template. Virology1988;163:123. CrossRef

94. GerlichW, RobinsonWS. Hepatitis B virus contains protein attached to the 5′ end of its complete strand. Cell1980;21:801. CrossRef

95. HattonT, ZhouS, StandringDN. RNA‐ and DNA‐binding activities in hepatitis B virus capsid protein: a model for their roles in viral replication. J Virol1992;66:5232.

96. ChenY, KewMC, HornbuckleWE, et al.The precore gene of the woodchuck hepatitis virus genome is not essential for viral replication in the natural host. J Virol1992;66:5682.

97. MilichDR, JonesJE, HughesJL, et al.Is a function of the secreted hepatits B e antigen to induce immunologic tolerance in utero?Proc Natl Acad Sci USA.1990;87:6599. CrossRef

98. CrossJC, WenP, RutterW. Transactivation by hepatitis B virus X protein is promiscuous and dependent on mitogen‐activated cellular serine/threonine kinases. Proc Natl Acad Sci USA.1993;90:8078. CrossRef

99. DoriaM, KleinN, LucitoR, et al.The hepatitis B virus HBx protein is a dual specificity cytoplasmic activator of Ras and nuclear activator of transcription factors. EMBO J1995;14:4747.

100. SitterlinD, LeeTH, PrigentS, et al.Interaction of the UV‐damaged DNA‐binding protein with hepatitis B virus X protein is conserved among mammalian hepadnaviruses and restricted to transactivation‐proficient X‐insertion mutants. J Virol1997;71:6194.

101. ChenH‐S, KanekoS, GironesR, et al.The woodchuck hepatitis X gene is important for establishment of virus infection in woodchucks. J Virol1993;67:1218.

102. ZoulimF, SaputelliJ, SeegerC. Woodchuck hepatitis virus X protein is required for viral infection in vivo. J Virol1994;68:2026.

103. CaselmannWH. Trans‐activation of cellular genes by hepatitis B virus proteins: a possible mechanism of hepatocarcinogenesis. Adv Virus Res1996;47:253. CrossRef

104. SeegerC, GanemD, VarmusHE. Genetic and biochemical evidence for the hepatitis B virus replication strategy. Science1986;232:477. CrossRef

105. YeeJ. A liver‐specific enhancer in the core promoter region of human hepatitis B virus. Science1989;246:658. CrossRef

106. Tur‐KaspaR, BurkR, ShaulY, et al.Hepatitis B virus DNA contains a glucocortcoid response element. Proc Natl Acad Sci USA.1986;83:1627. CrossRef

107. CattaneoR, WillH, HernandezN, et al.Signals regulating hepatitis B surface antigen transcription. Nature1983;305:336. CrossRef

108. HuangJ, LiangTJ. A novel hepatitis B virus (HBV) genetic element with Rev response element‐like properties that is essential for expression of HBV gene products. Mol Cell Biol1993;13:7476. CrossRef

109. KlingmullerU, SchallerH. Hepadnavirus infection requires interaction between the viral pre‐S domain and a specific hepatocellular receptor. J Virol1993;67:7414.

110. BreinerKM, UrbanS, SchallerH. Carboxypeptidase D (gp180), a Golgi‐resident protein, functions in the attachment and entry of avian hepatitis B viruses. J Virol1998;72:8098.

111. YanH, ZhongG, XuG, et al.Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife2012;1:e00049.

112. KockJ. Schilicht H‐J. Analysis of the earliest steps of hepadnavirus replication genome repair after infectious entry into hepatocytes does not depend on viral polymerase activity. J Virol1993;67:4867.

113. RoossinckMJ, JameelS, LoukinSH, et al.Expression of hepatitis B viral core region in mammalian cells. Mol Cell Biol1986;6:1393. CrossRef

114. Jean‐JeanO, WeimerT, de RecondoAM, et al.Internal entry of ribosomes and ribosomal scanning involved in hepatitis B virus P gene expression. J Virol1989;63:5451.

115. PersingDH, VarmusHE, GanemD. The preS1 protein of hepatitis B virus is acylated at its amino terminus with myristic acid. J Virol1987;61:1672.

116. PollackJ, GanemD. An RNA stem‐loop structure directs hepatitis B virus genomic RNA encapsidation. J Virol1993;67:3254.

117. PollackJ, GanemD. Site‐specific RNA binding by a hepatitis B virus reverse transcrptase initiates two reactions: RNA packaging and DNA synthesis. J Virol1994;68:5579.

118. WillH, ReiserW, WeimerT, et al.Replication strategy of human hepatitis B virus. J Virol1987;61:904.

119. HijikataM, ShimizuYK, KatoH, et al.Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol1993;67:1953.

120. ThomssenR, BonkS, ThielA. Density heterogeneities of hepatitis C virus in human sera due to the binding of beta‐lipoproteins and immunoglobulins. Med Microbiol Immunol1993;182:329. CrossRef

121. ChooQ, RichmanKH, HanJH, et al.Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci USA.1991;88:2451. CrossRef

122. HanJH, ShyamalaV, RichmanKH, et al.Characterization of the terminal regions of hepatitis C viral RNA: identification of conserved sequences in the 5′ untranslated region and poly (A) tails at the 3′ end. Proc Natl Acad Sci USA.1991;88:1711. CrossRef

123. KolykhalovAA, FeinstoneSM, RiceCM. Identification of a highly conserved sequence element at the 3′ terminus of hepatitis C virus genome RNA. J Virol1996;70:3363.

124. GrakouiA, WychowskiC, LinC, et al.Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol1993;67:1385.

125. HijikataM, KatoN, OotsuyamaY, et al.Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. Proc Natl Acad Sci USA.1991;88:5547. CrossRef

126. HijikataM, MizushimaH, AkagiT, et al.Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol1993;67:4665.

127. MiyamuraT, MatsuuraY. Structural proteins of hepatitis C virus. Trends Microbiol1993;1:229. CrossRef

128. WeinerAJ, BrauerMJ, RosenblattJ, et al.Variable and hypervariable domains are found in the regions of HCV corresponding to the flavivirus envelope and NS1 proteins and the pestivirus envelope glycoproteins. Virology1991;180:842. CrossRef

129. GrakouiA, McCourtDW, WychowskiC, et al.A second hepatitis C virus‐encoded proteinase. Proc Natl Acad Sci USA.1993;90:10583. CrossRef

130. HongZ, FerrariE, Wright‐MinogueJ, et al.Enzymatic characterization of hepatitis C virus NS3/4A complexes expressed in mammalian cells by using the herpes simplex virus amplicon system. J Virol1996;70:4261.

131. TomeiL, FaillaC, SantoliniE, et al.NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol1993;67:4017.

132. BartenschlagerR, LohmannV, WilkinsonT, et al.Complex formation between the NS3 serine‐type proteinase of the hepatitis C virus and NS4A and its importance for polyprotein maturation. J Virol1995;69:7519.

133. KimJL, MorgensternKA, LinC, et al.Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell1996;87:343. CrossRef

134. GosertR, EggerD, LohmannV, et al.Identification of the hepatitis C virus RNA replication complex in Huh‐7 cells harboring subgenomic replicons. J Virol2003;77:5487. CrossRef

135. BartenschlagerR, CossetFL, LohmannV. Hepatitis C virus replication cycle. J Hepatol2010;53:583. CrossRef

136. OhJW, ItoT, LaiMM. A Recombinant Hepatitis C Virus RNA‐Dependent RNA Polymerase Capable of Copying the Full‐Length Viral RNA. J Virol1999;73:7694.

137. HuangH, SunF, OwenDM, et al.Hepatitis C virus production by human hepatocytes dependent on assembly and secretion of very low‐density lipoproteins. Proc Natl Acad Sci U S A2007;104:5848. CrossRef

138. RizzettoM, CaneseMG, GerinJL, et al.Transmission of the hepatitis B virus‐associated delta antigen to chimpanzees. J Infect Dis1980;141:590. CrossRef

139. BranchAD, LevineBL, RobertsonHD. The brotherhood of circular RNA pathogens: viroids, circular satellites, and the delta agent. Sem Virol1990;1:143.

140. SureauC, MoriartyAM, ThorntonGB, et al.Production of infectious hepatitis delta virus in vitro and neutralization with antibodies directed against hepatitis B virus pre‐S antigens. J Virol1992;66:1241.

141. FuT‐B, TaylorJ. The RNAs of hepatitis delta virus are copied by RNA polymerase II in nuclear homogenates. J Virol1993;67:6965.

142. YamaguchiY, FilipovskaJ, YanoK, et al.Stimulation of RNA polymerase II elongation by hepatitis delta antigen. Science2001;293:124. CrossRef

143. HsiehS‐Y, TaylorJM. Regulation of polyadenylation of HDV antigenomic RNA. J Virol1991;65:6438.

144. WeinerAJ, ChooQ‐L, WangK‐S, et al.A single antigenomic open reading frame of the hepatitis delta virus encodes the epitope(s) of both hepatitis delta antigen polypeptides p24 and p27. J Virol1988;62:594.

145. KuoMY‐P, SharmeenL, Dinter‐GottliebG, et al.Characterization of self‐cleaving RNA sequences on the genome and antigenome of human hepatitis delta virus. J Virol1988;62:1855.

146. CaseyJL, GerinJL. Hepatitis delta virus: RNA editing and genotype variations. In: Dinter‐GottliebG(ed). The Unique Hepatitis Delta Virus. Heidelberg: Springer‐Verlag, 1995: 111.

147. ChaoM, HsiehS‐Y, TaylorJ. Role of two forms of the hepatitis delta virus antigen: evidence for a mechanism of self‐limiting genome replication. J Virol1990;64:5066.

148. RyuW‐S, NetterHJ, BayerM, et al.The ribonucleoprotein complexes of hepatitis delta virus. J Virol1993;67:3281.

149. ChangFL, ChenPJ, TuSJ, et al.The large form of hepatitis delta antigen is crucial for assembly of hepatitis delta virus. Proc Natl Acad Sci U S A1991;88:8490. CrossRef

150. EmersonSU, AndersonD, ArankalleA, et al.Hepevirus. In: FauquetCM, MayoMA, ManiloffJ, et al. (eds). Virus Taxonomy: VIIIth report of the International Committee on Taxonomy of Viruses. London: Elsevier/Academic Press, 2004: 851.

151. TamAW, SmithMM, GuerraME, et al.Hepatitis E virus (HEV): molecular cloning and sequencing of the full‐length viral genome. Virology1991;185:120. CrossRef

152. ReyesGR, PurdyMA, KimJP, et al.Isolation of a cDNA from the virus responsible for enterically transmitted non‐A, non‐B hepatitis. Science1990;247:1335. CrossRef

153. KooninEV, GorbalenyaAE, PurdyMA, et al.Computer‐assisted assignment of functional domains in the nonstructural polyprotein of hepatitis E virus: delineation of an additional group of positive‐strand RNA plant and animal viruses. Proc Natl Acad Sci U S A1992;89:8259. CrossRef

154. KorbaBE, CotePJ, WellsFV, et al.Natural history of woodchuck hepatitis virus infections during the course of experimental viral infection: molecular virologic features of the liver and lymphoid tissues. J Virol1989;63:1360.

155. ShimizuYK, IwamotoA, HijikataM, et al.Evidence for in vitro replication of hepatitis C virus genome in a human T‐cell line. Proc Natl Acad Sci U S A1992;89:5477. CrossRef

156. ThomasE, GonzalezVD, LiQ, et al.HCV infection induces a unique hepatic innate immune response associated with robust production of type III interferons. Gastroenterology2012;142:978. CrossRef

157. ThimmeR, BinderM, BartenschlagerR. Failure of innate and adaptive immune responses in controlling hepatitis C virus infection. FEMS Microbiol Rev2012;36:663. CrossRef

158. LiK, LemonSM. Innate immune responses in hepatitis C virus infection. Semin Immunopathol2013;35:53. CrossRef

159. BendelacA, RiveraMN, ParkSH, et al.Mouse CD1‐specific NK1 T cells: development, specificity, and function. Annu Rev Immunol1997;15:535. CrossRef

160. BironCA, NguyenKB, PienGC, et al.Natural killer cells in antiviral defense: function and regulation by innate cytokines. Annu Rev Immunol1999;17:189. CrossRef

161. GuidottiLG, RochfordR, ChungJ, et al.Viral clearance without destruction of infected cells during acute HBV infection. Science1999;284:825. CrossRef

162. ZeissigS, MurataK, SweetL, et al.Hepatitis B virus‐induced lipid alterations contribute to natural killer T cell‐dependent protective immunity. Nat Med2012;18:1060. CrossRef

163. ParkerDC. T cell‐dependent B cell activation. Annu Rev Immunol1993;11:331. CrossRef

164. StapletonJT. Host immune response to hepatitis A virus. J Infect Dis1995;171(Suppl 1):S9. CrossRef

165. SchofieldDJ, GlamannJ, EmersonSU, et al.Identification by phage display and characterization of two neutralizing chimpanzee monoclonal antibodies to the hepatitis E virus capsid protein. J Virol2000;74:5548. CrossRef

166. KrugmanS, OverbyLR, MushahwarIK, et al.Viral hepatitis, type B. Studies on natural history and prevention re‐examined. N Engl J Med1979;300:101. CrossRef

167. LiangTJ, RehermannB, SeeffLB, et al.Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med2000;132:296. CrossRef

168. LiangTJ. Current progress in development of hepatitis C virus vaccines. Nat Medicine2013;19:869. CrossRef

169. CasinoC, LilliD, RivaneraD, et al.Diagnostic value of anti‐hepatitis C virus (HCV) core immunoglobulin M in recurrence of HCV infection after orthotopic liver transplantation. J Clin Microbiol1999;37:2726.

170. BaumertTF, WellnitzS, AonoS, et al.Antibodies against hepatitis C virus‐like particles and viral clearance in acute and chronic hepatitis C. Hepatology2000;32:610. CrossRef

171. MilichDR, McLachlanA. The nucleocapsid of hepatitis B virus is both a T‐cell‐independent and a T‐cell‐dependent antigen. Science1986;234:1398. CrossRef

172. ChisariFV, FerrariC. Hepatitis B virus immunopathogenesis. Ann Rev Immunol1995;13:29. CrossRef

173. MichalakTI, LinB. Molecular species of hepadnavirus core and envelope polypeptides in hepatocyte plasma membrane of woodchucks with acute and chronic viral hepatitis. Hepatology1994;20:275.

174. SchlichtHJ, von BrunnA, TheilmannL. Antibodies in anti‐HBe‐positive patient sera bind to an HBe protein expressed on the cell surface of human hepatoma cells: implications for virus clearance. Hepatology1991;13:57.

175. FerrariC, PennaA, BertolettiA, et al.Cellular immune response to hepatitis B virus‐encoded antigens in acute and chronic hepatitis B virus infection. J Immunol1990;145:3442.

176. BoniC, BertolettiA, PennaA, et al.Lamivudine treatment can restore T cell responsiveness in chronic hepatitis B. J Clin Invest1998;102:968. CrossRef

177. MarinosG, TorreF, ChokshiS, et al.Induction of T‐helper cell response to hepatitis B core antigen in chronic hepatitis B: a major factor in activation of the host immune response to the hepatitis B virus. Hepatology1995;22:1040. CrossRef

178. RehermannB, ChangKM, McHutchinsonJ, et al.Differential cytotoxic T‐lymphocyte responsiveness to the hepatitis B and C viruses in chronically infected patients. J Virol1996;70:7092.

179. DiepolderHM, GerlachJT, ZachovalR, et al.Immunodominant CD4+ T‐cell epitope within nonstructural protein 3 in acute hepatitis C virus infection. J Virol1997;71:6011.

180. CooperS, EricksonAL, AdamsEJ, et al.Analysis of a successful immune response against hepatitis C virus. Immunity1999;10:439. CrossRef

181. LogvinoffC, MajorME, OldachD, et al.Neutralizing antibody response during acute and chronic hepatitis C virus infection. Proc Natl Acad Sci U S A2004;101:10149. CrossRef

182. BainC, FatmiA, ZoulimF, et al.Impaired allostimulatory function of dendritic cells in chronic hepatitis C infection. Gastroenterology2001;120:512. CrossRef

183. KittlesenDJ, Chianese‐BullockKA, YaoZQ, et al.Interaction between complement receptor gC1qR and hepatitis C virus core protein inhibits T‐lymphocyte proliferation. J Clin Invest2000;106:1239. CrossRef

184. GaleMJr, KwieciszewskiB, DossettM, et al.Antiapoptotic and oncogenic potentials of hepatitis C virus are linked to interferon resistance by viral repression of the PKR protein kinase. J Virol1999;73:6506.

185. AndoK, GuidottiLG, WirthS, et al.Class I‐restricted cytotoxic T lymphocytes are directly cytopathic for their target cells in vivo. J Immunol1994;152:3245.

186. MoriyamaT, GuilhotS, KlopchinK, et al.Immunobiology and pathogenesis of hepatocellular injury in hepatitis B virus transgenic mice. Science1990;248:361. CrossRef

187. AndoK, MoriyamaT, GuidottiLG, et al.Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med1993;178:1541. CrossRef

188. GuidottiLG, GuilhotS, ChisariFV. Interleukin‐2 and alpha/beta interferon down‐regulate hepatitis B virus gene expression in vivo by tumor necrosis factor‐dependent and – independent pathways. J Virol1994;68:1265.

189. LiangTJ, BaruchY, Ben‐PorathE, et al.Hepatitis B virus infection in patients with idiopathic liver disease. Hepatology1991;13:1044.

190. PaterliniP, GerkenG, NakajimaE, et al.Polymerase chain reaction to detect hepatitis B virus DNA and RNA sequences in primary liver cancers from patients negative for hepatitis B surface antigen. N Engl J Med1990;323:80. CrossRef

191. YamamotoK, HorikitaM, TsudaF, et al.Naturally occurring escape mutants of hepatitis B virus with various mutations in the S gene in carriers seropositive for antibody to hepatitis B surface antigen. J Virol1994;68:2671.

192. DicksonRC, EverhartJE, LakeJR, et al.Transmission of hepatitis B by transplantation of livers from donors positive for antibody to hepatitis B core antigen. The National Institute of Diabetes and Digestive and Kidney Diseases Liver Transplantation Database. Gastroenterology1997;113:1668. CrossRef

193. LokAS, LiangRH, ChiuEK, et al.Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy. Report of a prospective study. Gastroenterology1991;100:182.

194. ThiersV, NakajimaE, KremsdorfD, et al.Transmission of hepatitis B from hepatitis‐B‐seronegative subjects. Lancet1988;2:1273. CrossRef

195. TakakiA, WieseM, MaertensG, et al.Cellular immune responses persist and humoral responses decrease two decades after recovery from a single‐source outbreak of hepatitis C. Nat Med2000;6:578. CrossRef

196. FarciP, AlterHJ, GovindarajanS, et al.Lack of protective immunity against reinfection with hepatitis C virus. Science1992;258:135. CrossRef

197. PrinceAM, BrotmanB, HuimaT, et al.Immunity in hepatitis C infection. J Infect Dis1992;165:438. CrossRef

198. NascimbeniM, MizukoshiE, BosmannM, et al.Kinetics of CD4+ and CD8+ memory T‐cell responses during hepatitis C virus rechallenge of previously recovered chimpanzees. J Virol2003;77:4781. CrossRef

199. LanfordRE, GuerraB, ChavezD, et al.Cross‐genotype immunity to hepatitis C virus. J Virol2004;78:1575. CrossRef

200. ShoukryNH, GrakouiA, HoughtonM, et al.Memory CD8+ T cells are required for protection from persistent hepatitis C virus infection. J Exp Med2003;197:1645. CrossRef

201. KuraneI, BinnLN, BancroftWH, et al.Human lymphocyte responses to hepatitis A virus‐infected cells: interferon production and lysis of infected cells. J Immunol1985;135:2140.

202. VallbrachtA, FleischerB. Immune pathogenesis of hepatitis A. Arch Virol Suppl1992;4:3. CrossRef

203. RoutenbergJA, DienstagJL, HarrisonWO, et al.Foodborne outbreak of hepatitis A: clinical and laboratory features of acute and protracted illness. Am J Med Sci1979;278:123. CrossRef

204. StewartJS, FarrowLJ, CliffordRE, et al.A three‐year survey of viral hepatitis in West London. Q J Med1978;47:365.

205. AlterHJ, HollandPV, MorrowAG, et al.Clinical and serological analysis of transfusion‐associated hepatitis. Lancet1975;2:838. CrossRef

206. SmithFR, HenkinRI, DellRB. Disordered gustatory acuity in liver disease. Gastroenterology1976;70:568.

207. PerrilloRP, PohlDA, RoodmanST, et al.Acute non‐A, non‐B hepatitis with serum sickness‐like syndrome and aplastic anemia. JAMA1981;245:494. CrossRef

208. DienstagJL. Hepatitis B as an immune complex disease. Semin Liver Dis1981;1:45. CrossRef

209. TrepoC, ThivoletJ. Hepatitis associated antigen and periarteritis nodosa (PAN). Vox Sang1970;19:410. CrossRef

210. TrepoC, GuillevinL. Polyarteritis nodosa and extrahepatic manifestations of hbv infection: the case against autoimmune intervention in pathogenesis. J Autoimmun2001;16:269. CrossRef

211. GuillevinL, LhoteF, CohenP, et al.Polyarteritis nodosa related to hepatitis B virus. A prospective study with long‐term observation of 41 patients. Medicine (Baltimore)1995;74:238. CrossRef

212. MarcellinP, CalmusY, TakahashiH, et al.Latent hepatitis B virus (HBV) infection in systemic necrotizing vasculitis. Clin Exp Rheumatol1991;9:23.

213. LunelF, MussetL, CacoubP, et al.Cryoglobulinemia in chronic liver diseases: role of hepatitis C virus and liver damage. Gastroenterology1994;106:1291.

214. LevoY, GorevicPD, KassabHJ, et al.Association between hepatitis B virus and essential mixed cryoglobulinemia. N Engl J Med1977;296:1501. CrossRef

215. InmanRD, HodgeM, JohnstonME, et al.Arthritis, vasculitis, and cryoglobulinemia associated with relapsing hepatitis A virus infection. Ann Intern Med1986;105:700. CrossRef

216. AgnelloV, ChungRT, KaplanLM. A role for hepatitis C virus infection in type II cryoglobulinemia. N Engl J Med1992;327:1490. CrossRef

217. MisianiR, BellavitaP, FeniliD, et al.Hepatitis C virus infection in patients with essential mixed cryoglobulinemia. Ann Intern Med1992;117:573. CrossRef

218. FerriC, MontiM, La CivitaL, et al.Infection of peripheral blood mononuclear cells by hepatitis C virus in mixed cryoglobulinemia. Blood1993;82:3701.

219. SansonnoD, De VitaS, IacobelliAR, et al.Clonal analysis of intrahepatic B cells from HCV‐infected patients with and without mixed cryoglobulinemia. J Immunol1998;160:3594.

220. KunkelHG, AgnelloV, JoslinFG, et al.Cross‐idiotypic specificity among monoclonal IgM proteins with anti‐‐globulin activity. J Exp Med1973;137:331. CrossRef

221. CacoubP, FabianiFL, MussetL, et al.Mixed cryoglobulinemia and hepatitis C virus. Am J Med1994;96:124. CrossRef

222. TakekoshiY, TanakaM, ShidaN, et al.Strong association between membranous nephropathy and hepatitis‐B surface antigenaemia in Japanese children. Lancet1978;2:1065. CrossRef

223. TakekoshiY, TanakaM, MiyakawaY, et al.Free "small" and IgG‐associated "large" hepatitis B e antigen in the serum and glomerular capillary walls of two patients with membranous glomerulonephritis. N Engl J Med1979;300:814. CrossRef

224. SansonnoD, GesualdoL, MannoC, et al.Hepatitis C virus‐related proteins in kidney tissue from hepatitis C virus‐infected patients with cryoglobulinemic membranoproliferative glomerulonephritis. Hepatology1997;25:1237. CrossRef

225. LaiKN, LiPK, LuiSF, et al.Membranous nephropathy related to hepatitis B virus in adults. N Engl J Med1991;324:1457. CrossRef

226. IidaH, IzuminoK, AsakaM, et al.Membranoproliferative glomerulonephritis associated with chronic hepatitis B in adults: pathogenetic role of HBsAg. Am J Nephrol1987;7:319. CrossRef

227. LaiKN, LaiFM. Clinical features and the natural course of hepatitis B virus‐related glomerulopathy in adults. Kidney Int Suppl1991;35:S40.

228. JohnsonRJ, GretchDR, YamabeH, et al.Membranoproliferative glomerulonephritis associated with hepatitis C virus infection. N Engl J Med1993;328:465. CrossRef

229. IshimaruY, IshimaruH, TodaG, et al.An epidemic of infantile papular acrodermatitis (Gianotti's disease) in Japan associated with hepatitis‐B surface antigen subtype ayw. Lancet1976;1:707. CrossRef

230. LeeS, KimKY, HahnCS, et al.Gianotti‐Crosti syndrome associated with hepatitis B surface antigen (subtype adr). J Am Acad Dermatol1985;12:629. CrossRef

231. WillnerIR, UhlMD, HowardSC, et al.Serious hepatitis A: an analysis of patients hospitalized during an urban epidemic in the United States. Ann Intern Med1998;128:111. CrossRef

232. PelletierG, ElghoziD, TrepoC, et al.Mononeuritis in acute viral hepatitis. Digestion1985;32:53. CrossRef

233. TaborE. Guillain‐Barre syndrome and other neurologic syndromes in hepatitis A, B, and non‐A, non‐B. J Med Virol1987;21:207. CrossRef

234. WillsonRA. Extrahepatic manifestations of chronic viral hepatitis. Am J Gastroenterol1997;92:3.

235. Centers for Disease Control and Prevention (CDC). Guidelines For Viral Hepatitis Surveillance And Case Management. Available at:http://www.cdc.gov/hepatitis/statistics/surveillanceguidelines.htm. Acessed April 9, 2013.

236. LiawYF, YangCY, ChuCM, et al.Appearance and persistence of hepatitis A IgM antibody in acute clinical hepatitis A observed in an outbreak. Infection1986;14:156. CrossRef

237. LemonSM, BrownCD, BrooksDS, et al.Specific immunoglobulin M response to hepatitis A virus determined by solid‐phase radioimmunoassay. Infect Immun1980;28:927.

238. KaoHW, AshcavaiM, RedekerAG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology1984;4:933. CrossRef

239. AlterHJ, SeeffLB, KaplanPM, et al.Type B hepatitis: the infectivity of blood positive for E antigen and DNA polymerase after accidental needlestick exposure. N Engl J Med1976;295:909. CrossRef

240. HoofnagleJH, GeretyRJ, BarkerLF. Antibody to hepatitis B core antigen. Am J Med Sci1975;270:179. CrossRef

241. PerrilloRP, ChauKH, OverbyLR, et al.Anti‐hepatitis B core immunoglobulin M in the serologic evaluation of hepatitis B virus infection and simultaneous infection with type B, delta agent, and non‐A, non‐B viruses. Gastroenterology1983;85:163.

242. PawlotskyJM, DusheikoG, HatzakisA, et al.Virologic monitoring of hepatitis B virus therapy in clinical trials and practice: recommendations for a standardized approach. Gastroenterology2008;134:405. CrossRef

243. AlterMJ, MargolisHS, KrawczynskiK, et al.The natural history of community‐acquired hepatitis C in the United States. The Sentinel Counties Chronic non‐A, non‐B Hepatitis Study Team. N Engl J Med1992;327:1899. CrossRef

244. VrielinkH, ReesinkHW, van den BurgPJ, et al.Performance of three generations of anti‐hepatitis C virus enzyme‐linked immunosorbent assays in donors and patients. Transfusion1997;37:845. CrossRef

245. LeeSR, WoodCL, LaneMJ, et al.Increased detection of hepatitis C virus infection in commercial plasma donors by a third‐generation screening assay. Transfusion1995;35:845.

246. AlterHJ, PurcellRH, ShihJW, et al.Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non‐A, non‐B hepatitis. N Engl J Med1989;321:1494. CrossRef

247. FarciP, AlterHJ, WongD, et al.A long‐term study of hepatitis C virus replication in non‐A, non‐B hepatitis. N Engl J Med1991;325:98. CrossRef

248. MastEE, AlterMJ, HollandPV, et al.Evaluation of assays for antibody to hepatitis E virus by a serum panel. Hepatitis E Virus Antibody Serum Panel Evaluation Group. Hepatology1998;27:857. CrossRef

249. WrobleskiF. The clinical significance of transamianse activities in serum. Am J Med1959;27:911. CrossRef

250. CooperWC, GershonRK, SunSC, et al.Anicteric viral hepatitis. A clinicopathological follow‐up study in Taiwan. N Engl J Med1966;274:585. CrossRef

251. ScheuerPJ, DaviesSE, DhillonAP. Histopathological aspects of viral hepatitis. J Viral Hepat1996;3:277. CrossRef

252. IshakKG. Light microscopic morphology of viral hepatitis. Am J Clin Pathol1976;65:787.

253. PetersRL. Viral hepatitis: a pathologic spectrum. Am J Med Sci1975;270:17. CrossRef

254. BoyerJL, KlatskinG. Pattern of necrosis in acute viral hepatitis. Prognostic value of bridging (subacute hepatic necrosis). N Engl J Med1970;283:1063. CrossRef

255. YapSH, WillemsM, Van den OordJ, et al.Detection of hepatitis C virus antigen by immuno‐histochemical staining: a histological marker of hepatitis C virus infection. J Hepatol1994;20:275. CrossRef

256. Gonzalez‐PeraltaRP, FangJW, DavisGL, et al.Optimization for the detection of hepatitis C virus antigens in the liver. J Hepatol1994;20:143. CrossRef

257. CrapperRM, BhathalPS, MackayIR, et al.′Acute′ autoimmune hepatitis. Digestion1986;34:216. CrossRef

258. AmontreeJS, StuartTD, BredfeldtJE. Autoimmune chronic active hepatitis masquerading as acute hepatitis. J Clin Gastroenterol1989;11:303. CrossRef

259. Roche‐SicotJ, BenhamouJP. Acute intravascular hemolysis and acute liver failure associated as a first manifestation of Wilson's disease. Ann Intern Med1977;86:301. CrossRef

260. SchiodtFV, AtillasoyE, ShakilAO, et al.Etiology and outcome for 295 patients with acute liver failure in the United States. Liver Transpl Surg1999;5:29. CrossRef

261. WettendorffP, van GossumA, DelcourtA. Gallstones and acute hepatitis. Lancet1981;1:675. CrossRef

262. FujiiN, TakenakaK, ShinagawaK, et al.Hepatic graft‐versus‐host disease presenting as an acute hepatitis after allogeneic peripheral blood stem cell transplantation. Bone Marrow Transplant2001;27:1007. CrossRef

263. StrasserSI, ShulmanHM, FlowersME, et al.Chronic graft‐versus‐host disease of the liver: presentation as an acute hepatitis. Hepatology2000;32:1265. CrossRef

264. McDonaldGB, HindsMS, FisherLD, et al.Veno‐occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med1993;118:255. CrossRef

265. RielyCA, LathamPS, RomeroR, et al.Acute fatty liver of pregnancy. A reassessment based on observations in nine patients. Ann Intern Med1987;106:703. CrossRef

266. WeinsteinL. Syndrome of hemolysis, elevated liver enzymes, and low platelet count: a severe consequence of hypertension in pregnancy. Am J Obstet Gynecol1982;142:159.

267. KhakooSI, ThioCL, MartinMP, et al.HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science2004;305:872. CrossRef

268. ThomasDL, ThioCL, MartinMP, et al.Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature2009;461:798. CrossRef

269. SchiffER. Atypical clinical manifestations of hepatitis A. Vaccine1992;10(Suppl 1):S18. CrossRef

270. GordonSC, ReddyKR, SchiffL, et al.Prolonged intrahepatic cholestasis secondary to acute hepatitis A. Ann Intern Med1984;101:635. CrossRef

271. GliksonM, GalunE, OrenR, et al.Relapsing hepatitis A. Review of 14 cases and literature survey. Medicine (Baltimore)1992;71:14.

272. TannoH, FayOH, RojmanJA, et al.Biphasic form of hepatitis A virus infection: a frequent variant in Argentina. Liver1988;8:53. CrossRef

273. FainboimL, Canero VelascoMC, MarcosCY, et al.Protracted, but not acute, hepatitis A virus infection is strongly associated with HLA‐DRB*1301, a marker for pediatric autoimmune hepatitis. Hepatology2001;33:1512. CrossRef

274. RahamanSM, ChiraP, KoffRS. Idiopathic autoimmune chronic hepatitis triggered by hepatitis A. Am J Gastroenterol1994;89:106.

275. VentoS, GarofanoT, Di PerriG, et al.Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet1991;337:1183. CrossRef

276. RakelaJ, LangeSM, LudwigJ, et al.Fulminant hepatitis: Mayo Clinic experience with 34 cases. Mayo Clin Proc1985;60:289. CrossRef

277. TandonBN, JoshiYK, TandonM. Acute liver failure. Experience with 145 patients. J Clin Gastroenterol1986;8:664. CrossRef

278. NandaSK, YalcinkayaK, PanigrahiAK, et al.Etiological role of hepatitis E virus in sporadic fulminant hepatitis. J Med Virol1994;42:133. CrossRef

279. De CockKM, GovindarajanS, RedekerAG. Fulminant delta hepatitis in chronic hepatitis B infection. JAMA1984;252:2746. CrossRef

280. RakelaJ, PerkinsJD, GrossJBJr, et al.Acute hepatic failure: the emerging role of orthotopic liver transplantation. Mayo Clin Proc1989;64:424. CrossRef

281. O′GradyJG. Fulminant hepatitis in patients with chronic liver disease. J Viral Hepat2000;7(Suppl 1):9. CrossRef

282. VentoS, GarofanoT, RenziniC, et al.Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. N Engl J Med1998;338:286. CrossRef

283. AsselahT, BernuauJ, MarcellinP. Prevalence of hepatitis C virus infection in patients hospitalized for hepatitis A. Ann Intern Med1999;130:451. CrossRef

284. HelblingB, RennerEL, KammerlanderR. Acute hepatitis A in patients with chronic hepatitis C. Ann Intern Med1999;131:314. CrossRef

285. KosakaY, TakaseK, KojimaM, et al.Fulminant hepatitis B: induction by hepatitis B virus mutants defective in the precore region and incapable of encoding e antigen. Gastroenterology1991;100:1087.

286. LiangTJ, HasegawaK, RimonN, et al.A hepatitis B virus mutant associated with an epidemic of fulminant hepatitis. N Engl J Med1991;324:1705. CrossRef

287. OmataM, EhataT, YokosukaO, et al.Mutations in the precore region of hepatitis B virus DNA in patients with fulminant and severe hepatitis. N Engl J Med1991;324:1699. CrossRef

288. SatoS, SuzukiK, AkahaneY, et al.Hepatitis B virus strains with mutations in the core promoter in patients with fulminant hepatitis. Ann Intern Med1995;122:241. CrossRef

289. LaskusT, PersingDH, NowickiMJ, et al.Nucleotide sequence analysis of the precore region in patients with fulminant hepatitis B in the United States. Gastroenterology1993;105:1173.

290. SterneckM, GuntherS, SantantonioT, et al.Hepatitis B virus genomes of patients with fulminant hepatitis do not share a specific mutation. Hepatology1996;24:300. CrossRef

291. FerayC, GigouM, SamuelD, et al.Low prevalence of precore mutations in hepatitis B virus DNA in fulminant hepatitis type B in France. J Hepatol1993;18:119. CrossRef

292. OkamotoH, YotsumotoS, AkahaneY, et al.Hepatitis B viruses with precore region defects prevail in persistently infected hosts along with seroconversion to the antibody against e antigen. J Virol1990;64:1298.

293. KimJW, LeeHS, WooGH, et al.Fatal submassive hepatic necrosis associated with tyrosine‐methionine‐aspartate‐aspartate‐motif mutation of hepatitis B virus after long‐term lamivudine therapy. Clin Infect Dis2001;33:403. CrossRef

294. LiawYF, ChienRN, YehCT, et al.Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology1999;30:567. CrossRef

295. LettauLA, McCarthyJG, SmithMH, et al.Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med1987;317:1256. CrossRef

296. De CockKM, GovindarajanS, ChinKP, et al.Delta hepatitis in the Los Angeles area: a report of 126 cases. Ann Intern Med1986;105:108. CrossRef

297. BensabathG, HadlerSC, SoaresMC, et al.Hepatitis delta virus infection and Labrea hepatitis. Prevalence and role in fulminant hepatitis in the Amazon Basin. JAMA1987;258:479. CrossRef

298. CaseyJL, BrownTL, ColanEJ, et al.A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A1993;90:9016. CrossRef

299. TsegaE, HanssonBG, KrawczynskiK, et al.Acute sporadic viral hepatitis in Ethiopia: causes, risk factors, and effects on pregnancy. Clin Infect Dis1992;14:961. CrossRef

300. KhurooMS, TeliMR, SkidmoreS, et al.Incidence and severity of viral hepatitis in pregnancy. Am J Med1981;70:252. CrossRef

301. BrownKE, TisdaleJ, BarrettAJ, et al.Hepatitis‐associated aplastic anemia. N Engl J Med1997;336:1059. CrossRef

302. IdeT, SataM, NounoR, et al.Clinical evaluation of four cases of acute viral hepatitis complicated by pure red cell aplasia. Am J Gastroenterol1994;89:257.

303. HaglerL, PastoreRA, BerginJJ, et al.Aplastic anemia following viral hepatitis: report of two fatal cases and literature review. Medicine (Baltimore)1975;54:139. CrossRef

304. YoungNS, IssaragrasilS, ChiehCW, et al.Aplastic anaemia in the Orient. Br J Haematol1986;62:1. CrossRef

305. MosleyJW, ReislerDM, BrachottD, et al.Comparison of two lots of immune serum globulin for prophylaxis of infectious hepatitis. Am J Epidemiol1968;87:539.

306. StokesJ, NeefeJR. The prevention and attenuation of infectious hepatitis by gamma globulin: preliminary note. JAMA1945;127:144. CrossRef

307. EllisEF, HenneyCS. Adverse reactions following administration of human gamma globulin. J Allergy1969;43:45. CrossRef

308. Advisory Committee on Immunization Practices (ACIP). Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep1999;48(RR–12):1.

309. ClemensR, SafaryA, HepburnA, et al.Clinical experience with an inactivated hepatitis A vaccine. J Infect Dis1995;171(Suppl 1):S44. CrossRef

310. NalinDR, KuterBJ, BrownL, et al.Worldwide experience with the CR326F‐derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol1993;18(Suppl 2):S51. CrossRef

311. InnisBL, SnitbhanR, KunasolP, et al.Protection against hepatitis A by an inactivated vaccine. JAMA1994;271:1328. CrossRef

312. WerzbergerA, MenschB, KuterB, et al.A controlled trial of a formalin‐inactivated hepatitis A vaccine in healthy children. N Engl J Med1992;327:453. CrossRef

313. VictorJC, MontoAS, SurdinaTY, et al.Hepatitis A vaccine versus immune globulin for postexposure prophylaxis. N Engl J Med2007;357:1685. CrossRef

314. Van HerckK, JacquetJM, Van DammeP. Antibody persistence and immune memory in healthy adults following vaccination with a two‐dose inactivated hepatitis A vaccine: long‐term follow‐up at 15 years. J Med Virol2011;83:1885. CrossRef

315. RaczniakGA, BulkowLR, BruceMG, et al.Long‐term immunogenicity of hepatitis A virus vaccine in Alaska 17 years after initial childhood series. J Infect Dis2013;207:493. CrossRef

316. Centers for Disease Control and Prevention (CDC). Vaccine Information Statements. Hepatitis A VIS. Available at: http://www.cdc.gov/vaccines/pubs/vis/downloads/vis-hep-a.pdf. Accessed April 9, 2013.

317. AmbroschF, AndreFE, DelemA, et al.Simultaneous vaccination against hepatitis A and B: results of a controlled study. Vaccine1992;10(Suppl 1):S142. CrossRef

318. HessG, ClemensR, BienzleU, et al.Immunogenicity and safety of an inactivated hepatitis A vaccine in anti‐HIV positive and negative homosexual men. J Med Virol1995;46:40. CrossRef

319. KeeffeEB, IwarsonS, McMahonBJ, et al.Safety and immunogenicity of hepatitis A vaccine in patients with chronic liver disease. Hepatology1998;27:881. CrossRef

320. LeeSD, ChanCY, YuMI, et al.Safety and immunogenicity of inactivated hepatitis A vaccine in patients with chronic liver disease. J Med Virol1997;52:215. CrossRef

321. LaurenceJC. Hepatitis A and B immunizations of individuals infected with human immunodeficiency virus. Am J Med2005;118(Suppl 10A):75S. CrossRef

322. NeilsenGA, BodsworthNJ, WattsN. Response to hepatitis A vaccination in human immunodeficiency virus‐infected and ‐uninfected homosexual men. J Infect Dis1997;176:1064. CrossRef

323. Van DammeP, Van HerckK. A review of the efficacy, immunogenicity and tolerability of a combined hepatitis A and B vaccine. Expert Rev Vaccines2004;3:249. CrossRef

324. Van DammeP, Leroux‐RoelsG, CrastaP, et al.Antibody persistence and immune memory in adults, 15 years after a three‐dose schedule of a combined hepatitis A and B vaccine. J Med Virol2012;84:11. CrossRef

325. ZajacBA, WestDJ, McAleerWJ, et al.Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. J Infect1986;13(Suppl A):39. CrossRef

326. SzmunessW, StevensCE, HarleyEJ, et al.Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high‐risk population in the United States. N Engl J Med1980;303:833. CrossRef

327. JilgW, SchmidtM, DeinhardtF. Vaccination against hepatitis B: comparison of three different vaccination schedules. J Infect Dis1989;160:766. CrossRef

328. CoursagetP, FritzellB, BlondeauC, et al.Simultaneous injection of plasma‐derived or recombinant hepatitis B vaccines with yellow fever and killed polio vaccines. Vaccine1995;13:109. CrossRef

329. StevensCE, AlterHJ, TaylorPE, et al.Hepatitis B vaccine in patients receiving hemodialysis. Immunogenicity and efficacy. N Engl J Med1984;311:496. CrossRef

330. JilgW, SchmidtM, WeinelB, et al.Immunogenicity of recombinant hepatitis B vaccine in dialysis patients. J Hepatol1986;3:190. CrossRef

331. ReyD, KrantzV, PartisaniM, et al.Increasing the number of hepatitis B vaccine injections augments anti‐HBs response rate in HIV‐infected patients. Effects on HIV‐1 viral load. Vaccine2000;18:1161. CrossRef

332. StevensCE, TaylorPE, TongMJ, et al.Yeast‐recombinant hepatitis B vaccine. Efficacy with hepatitis B immune globulin in prevention of perinatal hepatitis B virus transmission. JAMA1987;257:2612. CrossRef

333. PoovorawanY, SanpavatS, PongpunlertW, et al.Protective efficacy of a recombinant DNA hepatitis B vaccine in neonates of HBe antigen‐positive mothers. JAMA1989;261:3278. CrossRef

334. FrancisDP, HadlerSC, ThompsonSE, et al.The prevention of hepatitis B with vaccine. Report of the centers for disease control multi‐center efficacy trial among homosexual men. Ann Intern Med1982;97:362. CrossRef

335. YuAS, CheungRC, KeeffeEB. Hepatitis B vaccines. Clin Liver Dis2004;8:283. CrossRef

336. HadlerSC, FrancisDP, MaynardJE, et al.Long‐term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. N Engl J Med1986;315:209. CrossRef

337. WainwrightRB, McMahonBJ, BulkowLR, et al.Duration of immunogenicity and efficacy of hepatitis B vaccine in a Yupik Eskimo population. JAMA1989;261:2362. CrossRef

338. Hepatitis B virus: a comprehensive strategy for eliminating transmission in the United States through universal childhood vaccination. Recommendations of the Immunization Practices Advisory Committee (ACIP). MMWR Morb Mortal Wkly Rep1991;40(RR–13):1.

339. LuCY, ChiangBL, ChiWK, et al.Waning immunity to plasma‐derived hepatitis B vaccine and the need for boosters 15 years after neonatal vaccination. Hepatology2004;40:1415. CrossRef

340. McMahonBJ, BrudenDL, PetersenKM, et al.Antibody levels and protection after hepatitis B vaccination: results of a 15‐year follow‐up. Ann Intern Med2005;142:333. CrossRef

341. McMahonBJ, BrudenDL, PetersenKM, et al.Antibody levels and protection after hepatitis B vaccination: results of a 15‐year follow‐up. Ann Intern Med2005;142:333. CrossRef

342. HuangK, LinS. Nationwide vaccination: a success story in Taiwan. Vaccine2000;18(Suppl 1):S35. CrossRef

343. ChangMH, ChenCJ, LaiMS, et al.Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med1997;336:1855. CrossRef

344. HsuHM, ChenDS, ChuangCH, et al.Efficacy of a mass hepatitis B vaccination program in Taiwan. Studies on 3464 infants of hepatitis B surface antigen‐carrier mothers. JAMA1988;260:2231. CrossRef

345. WhittleHC, MaineN, PilkingtonJ, et al.Long‐term efficacy of continuing hepatitis B vaccination in infancy in two Gambian villages. Lancet1995;345:1089. CrossRef

346. HsuHY, ChangMH, LiawSH, et al.Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology1999;30:1312. CrossRef

347. HsuHY, ChangMH, LiawSH, et al.Changes of hepatitis B surface antigen variants in carrier children before and after universal vaccination in Taiwan. Hepatology1999;30:1312. CrossRef

348. MeleA, TancrediF, RomanoL, et al.Effectiveness of hepatitis b vaccination in babies born to hepatitis b surface antigen‐positive mothers in italy. J Infect Dis2001;184:905. CrossRef

349. SoussanP, PolS, GarreauF, et al.Vaccination of chronic hepatitis B virus carriers with preS2/S envelope protein is not associated with the emergence of envelope escape mutants. J Gen Virol2001;82:367. CrossRef

350. BasuniAA, ButterworthL, CooksleyG, et al.Prevalence of HBsAg mutants and impact of hepatitis B infant immunisation in four Pacific Island countries. Vaccine2004;22:2791. CrossRef

351. OgataN, CotePJ, ZanettiAR, et al.Licensed recombinant hepatitis B vaccines protect chimpanzees against infection with the prototype surface gene mutant of hepatitis B virus. Hepatology1999;30:779. CrossRef

352. HerroelenL, de KeyserJ, EbingerG. Central‐nervous‐system demyelination after immunisation with recombinant hepatitis B vaccine. Lancet1991;338:1174. CrossRef

353. AscherioA, ZhangSM, HernanMA, et al.Hepatitis B vaccination and the risk of multiple sclerosis. N Engl J Med2001;344:327. CrossRef

354. ConfavreuxC, SuissaS, SaddierP, et al.Vaccinations and the risk of relapse in multiple sclerosis. Vaccines in Multiple Sclerosis Study Group. N Engl J Med2001;344:319. CrossRef

355. DittmannS. Special address: safety of hepatitis B vaccination. Vaccine2000;18(Suppl 1):S10. CrossRef

356. MastEE, MargolisHS, FioreAE, et al.A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep2005;54(RR–16):1.

357. FarciP, ShimodaA, WongD, et al.Prevention of hepatitis C virus infection in chimpanzees by hyperimmune serum against the hypervariable region 1 of the envelope 2 protein. Proc Natl Acad Sci U S A1996;93:15394. CrossRef

358. FarciP, AlterHJ, WongDC, et al.Prevention of hepatitis C virus infection in chimpanzees after antibody‐mediated in vitro neutralization. Proc Natl Acad Sci U S A1994;91:7792. CrossRef

359. ChooQL, KuoG, RalstonR, et al.Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A1994;91:1294. CrossRef

360. FolgoriA, CaponeS, RuggeriL, et al.A T‐cell HCV vaccine eliciting effective immunity against heterologous virus challenge in chimpanzees. Nat Med2006;12:190. CrossRef

361. BarnesE, FolgoriA, CaponeS, et al.Novel adenovirus‐based vaccines induce broad and sustained T cell responses to HCV in man. Sci Transl Med2012;4:115ra1. CrossRef

362. FreySE, HoughtonM, CoatesS, et al.Safety and immunogenicity of HCV E1E2 vaccine adjuvanted with MF59 administered to healthy adults. Vaccine2010;28:6367. CrossRef

363. StamatakiZ, CoatesS, AbrignaniS, et al.Immunization of human volunteers with hepatitis C virus envelope glycoproteins elicits antibodies that cross‐neutralize heterologous virus strains. J Infect Dis2011;204:811. CrossRef

364. SeeffLB, ZimmermanHJ, WrightEC, et al.A randomized, double blind controlled trial of the efficacy of immune serum globulin for the prevention of post‐transfusion hepatitis. A Veterans Administration cooperative study. Gastroenterology1977;72:111.

365. KrawczynskiK, AlterMJ, TankersleyDL, et al.Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis1996;173:822. CrossRef

366. KnodellRG, ConradME, GinsbergAL, et al.Efficacy of prophylactic gamma‐globulin in preventing non‐A, non‐B post‐transfusion hepatitis. Lancet1976;1:557. CrossRef

367. Sanchez‐QuijanoA, PinedaJA, LissenE, et al.Prevention of post‐transfusion non‐A, non‐B hepatitis by non‐specific immunoglobulin in heart surgery patients. Lancet1988;1:1245. CrossRef

368. YuMY, BartoschB, ZhangP, et al.Neutralizing antibodies to hepatitis C virus (HCV) in immune globulins derived from anti‐HCV‐positive plasma. Proc Natl Acad Sci U S A2004;101:7705. CrossRef

369. ShresthaMP, ScottRM, JoshiDM, et al.Safety and efficacy of a recombinant hepatitis E vaccine. N Engl J Med2007;356:895. CrossRef

370. ZhuFC, ZhangJ, ZhangXF, et al.Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large‐scale, randomised, double‐blind placebo‐controlled, phase 3 trial. Lancet2010;376:895. CrossRef

371. Advisory Committee on Immunization Practices (ACIP). Update: Prevention of hepatitis A after exposure to hepatitis A virus and in international travelers. MMWR Morb Mortal Wkly Rep2007;56:1080.

372. WernerBG, GradyGF. Accidental hepatitis‐B‐surface‐antigen‐positive inoculations. Use of e antigen to estimate infectivity. Ann Intern Med1982;97:367. CrossRef

373. PuroV, PetrosilloN, IppolitoG. Risk of hepatitis C seroconversion after occupational exposures in health care workers. Italian Study Group on Occupational Risk of HIV and Other Bloodborne Infections. Am J Infect Control1995;23:273. CrossRef

374. MitsuiT, IwanoK, MasukoK, et al.Hepatitis C virus infection in medical personnel after needlestick accident. Hepatology1992;16:1109. CrossRef

375. Centers for Disease Control (CDC). Recommendations for prevention of HIV transmission in health‐care settings. MMWR Morb Mortal Wkly Rep1987;36(Suppl 2):1S.

376. Occupational Safety and Health Administration (OSHA), U.S. Department of Labor. Occupational injury and illness recording and reporting requirements. Final rule. Fed Regist2001;66:5916.

377. Occupational Safety and Health Administration (OSHA), U.S. Department of Labor. Occupational exposure to bloodborne pathogens. Final rule. Fed Regist1991;56:64004.

378. U.S. Public Health Service. Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis. MMWR Morb Mortal Wkly Rep2001;50(RR–11):1.

379. JaeckelE, CornbergM, WedemeyerH, et al.Treatment of acute hepatitis C woth interferom alfa‐2b. N Engl J Med2001;345:1452. CrossRef

380. AllenC, GlasziouP, Del MarC. Bed rest: a potentially harmful treatment needing more careful evaluation. Lancet1999;354:1229. CrossRef

381. KunduSS, KunduAK, PalNK. Interferon‐alpha in the treatment of acute prolonged hepatitis B virus infection. J Assoc Physicians India2000l;48:671.

382. TassopoulosNC, KoutelouMG, PolychronakiH, et al.Recombinant interferon‐alpha therapy for acute hepatitis B: a randomized, double‐blind, placebo‐controlled trial. J Viral Hepat1997;4:387. CrossRef

383. KawaiY, IkegayaS, HataM, et al.Successful lamivudine therapy for post‐chemotherapeutic fulminant hepatitis B in a hepatitis B virus carrier with non‐Hodgkin's lymphoma: case report and review of the literature. Ann Hematol2001;80:482. CrossRef

384. EndoT, SakaiT, FujimotoK, et al.A possible role for lamivudine as prophylaxis against hepatitis B reactivation in carriers of hepatitis B who undergo chemotherapy and autologous peripheral blood stem cell transplantation for non‐Hodgkin's lymphoma. Bone Marrow Transplant2001;27:433. CrossRef

385. AndreoneP, CaraceniP, GraziGL, et al.Lamivudine treatment for acute hepatitis B after liver transplantation. J Hepatol1998;29:985. CrossRef

386. KondiliLA, OsmanH, MutimerD. The use of lamivudine for patients with acute hepatitis B (a series of cases). J Viral Hepat2004;11:427. CrossRef

387. Schmilovitz‐WeissH, Ben‐AriZ, SikulerE, et al.Lamivudine treatment for acute severe hepatitis B: a pilot study. Liver Int2004;24:547. CrossRef

388. TillmannHL, HademJ, LeifeldL, et al.Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hep2006;13:256. CrossRef

389. LauGK, YiuHH, FongDY, et al.Early is superior to deferred preemptive lamivudine therapy for hepatitis B patients undergoing chemotherapy. Gastroenterology2003;125:1742. CrossRef

390. YeoW, JohnsonPJ. Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy. Hepatology2006;43:209. CrossRef

391. MannsMP, McHutchisonJG, GordonSC, et al.Peginterferon alfa‐2b plus ribavirin compared with interferon alfa‐2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001;358:958. CrossRef

392. FriedMW, ShiffmanML, ReddyKR, et al.Peginterferon alfa‐2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med2002;347:975. CrossRef

393. HadziyannisSJ, SetteHJr, MorganTR, et al.Peginterferon‐alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med2004;140:346. CrossRef

394. OmataM, YokosukaO, TakanoS, et al.Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet1991;338:914. CrossRef

395. ViladomiuL, GenescaJ, EstebanJI, et al.Interferon‐alpha in acute posttransfusion hepatitis C: a randomized, controlled trial. Hepatology1992;15:767. CrossRef

396. LamperticoP, RumiM, RomeoR, et al.A multicenter randomized controlled trial of recombinant interferon‐ alpha 2b in patients with acute transfusion‐associated hepatitis C. Hepatology1994;19:19. CrossRef

397. TakanoS, SatomuraY, OmataM. Effects of interferon beta on non‐A, non‐B acute hepatitis: a prospective, randomized, controlled‐dose study. Japan Acute Hepatitis Cooperative Study Group. Gastroenterology1994;107:805. CrossRef

398. LicataA, Di BonaD, SchepisF, et al.When and how to treat acute hepatitis C?J Hepatol2003;39:1056. CrossRef

399. GerlachJT, DiepolderHM, ZachovalR, et al.Acute hepatitis C: high rate of both spontaneous and treatment‐induced viral clearance. Gastroenterology2003;125:80. CrossRef

400. WiegandJ, BuggischP, BoecherW, et al.Early monotherapy with pegylated interferon alpha‐2b for acute hepatitis C infection: the HEP‐NET acute‐HCV‐II study. Hepatology2006;43:250. CrossRef

401. DeterdingK, GrunerN, BuggischP, et al.Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non‐inferiority trial. Lancet Infect Dis2013;13:497. CrossRef

402. NomuraH, SouS, TanimotoH, et al.Short‐term interferon‐alfa therapy for acute hepatitis C: a randomized controlled trial. Hepatology2004;39:1213. CrossRef

403. LangenbergAG, CoreyL, AshleyRL, et al.A prospective study of new infections with herpes simplex virus type 1 and type 2. Chiron HSV Vaccine Study Group. N Engl J Med1999;341:1432. CrossRef

404. MasonA, SallieR, PerrilloR, et al.Prevalence of herpesviridae and hepatitis B virus DNA in the liver of patients with non‐A, non‐B fulminant hepatic failure. Hepatology1996;24:1361. CrossRef

405. FinkCG, ReadSJ, HopkinJ, et al.Acute herpes hepatitis in pregnancy. J Clin Pathol1993;46:968. CrossRef

406. KangAH, GravesCR. Herpes simplex hepatitis in pregnancy: a case report and review of the literature. Obstet Gynecol Surv1999;54:463. CrossRef

407. JohnsonJR, EgaasS, GleavesCA, et al.Hepatitis due to herpes simplex virus in marrow‐transplant recipients. Clin Infect Dis1992;14:38. CrossRef

408. IchaiP, AfonsoAM, SebaghM, et al.Herpes simplex virus‐associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl2005;11:1550. CrossRef

409. TomitaT, GarciaF, MowryM. Herpes simplex hepatitis before and after acyclovir treatment. Immunohistochemical and in situ hybridization study. Arch Pathol Lab Med1992;116:173.

410. van DoornumGJ, GuldemeesterJ, OsterhausAD, et al.Diagnosing herpesvirus infections by real‐time amplification and rapid culture. J Clin Microbiol2003;41:576. CrossRef

411. KleinNA, MabieWC, ShaverDC, et al.Herpes simplex virus hepatitis in pregnancy. Two patients successfully treated with acyclovir. Gastroenterology1991;100:239.

412. ShanleyCJ, BraunDK, BrownK, et al.Fulminant hepatic failure secondary to herpes simplex virus hepatitis. Successful outcome after orthotopic liver transplantation. Transplantation1995;59:145. CrossRef

413. NorvellJP, BleiAT, JovanovicBD, et al.Herpes simplex virus hepatitis: an analysis of the published literature and institutional cases. Liver Transpl2007;13:1428. CrossRef

414. JacobsonIM, GangDL, SchapiroRH. Epstein‐Barr viral hepatitis: an unusual case and review of the literature. Am J Gastroenterol1984;79:628.

415. LangnasAN, MarkinRS, InagakiM, et al.Epstein‐Barr virus hepatitis after liver transplantation. Am J Gastroenterol1994;89:1066.

416. PapatheodoridisGV, DelladetsimaJK, KavallierouL, et al.Fulminant hepatitis due to Epstein‐Barr virus infection. J Hepatol1995;23:348. CrossRef

417. BarkholtL, ReinholtFP, TeramotoN, et al.Polymerase chain reaction and in situ hybridization of Epstein‐Barr virus in liver biopsy specimens facilitate the diagnosis of EBV hepatitis after liver transplantation. Transpl Int1998;11:336. CrossRef

418. RandhawaPS, JaffeR, DemetrisAJ, et al.Expression of Epstein‐Barr virus‐encoded small RNA (by the EBER‐1 gene) in liver specimens from transplant recipients with post‐transplantation lymphoproliferative disease. N Engl J Med1992;327:1710. CrossRef

419. PisapiaR, MarianoA, RiandaA, et al.Severe EBV hepatitis treated with valganciclovir. Infection2013;41:251. CrossRef

420. AdamsLA, DeboerB, JeffreyG, et al.Ganciclovir and the treatment of Epstein‐Barr virus hepatitis. J Gastroenterol Hepatol2006;21:1758. CrossRef

421. FeranchakAP, TysonRW, NarkewiczMR, et al.Fulminant Epstein‐Barr viral hepatitis: orthotopic liver transplantation and review of the literature. Liver Transpl Surg1998;4:469. CrossRef

422. HoM. Epidemiology of cytomegalovirus infections. Rev Infect Dis1990;12(Suppl 7):S701. CrossRef

423. TarrPI, HaasJE, ChristieDL. Biliary atresia, cytomegalovirus, and age at referral. Pediatrics1996;97:828.

424. HorwitzCA, HenleW, HenleG, et al.Clinical and laboratory evaluation of cytomegalovirus‐induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore)1986;65:124. CrossRef

425. AgarwalSK, KalraV, DindaA, et al.Fibrosing cholestatic hepatitis in renal transplant recipient with CMV infection: a case report. Int Urol Nephrol2004;36:433. CrossRef

426. MacDonaldGA, GreensonJK, DelBuonoEA, et al.Mini‐microabscess syndrome in liver transplant recipients. Hepatology1997;26:192. CrossRef

427. BarkholtLM, EhrnstA, VeressB. Clinical use of immunohistopathologic methods for the diagnosis of cytomegalovirus hepatitis in human liver allograft biopsy specimens. Scand J Gastroenterol1994;29:553. CrossRef

428. RabahR, JaffeR. Early detection of cytomegalovirus in the allograft liver biopsy: a comparison of methods. Pediatr Pathol1987;7:549. CrossRef

429. AlterHJ, BradleyDW. Non‐A, non‐B hepatitis unrelated to the hepatitis C virus (non‐ABC). Semin Liver Dis1995;15:110. CrossRef

430. AlterHJ, NakatsujiY, MelpolderJ, et al.The incidence of transfusion‐associated hepatitis G virus infection and its relation to liver disease. N Engl J Med1997;336:747. CrossRef

431. AlterMJ, GallagherM, MorrisTT, et al.Acute non‐A‐E hepatitis in the United States and the role of hepatitis G virus infection. Sentinel Counties Viral Hepatitis Study Team. N Engl J Med1997;336:741. CrossRef

432. TillmannHL, HeikenH, Knapik‐BotorA, et al.Infection with GB virus C and reduced mortality among HIV‐infected patients. N Engl J Med2001;345:715. CrossRef

433. XiangJ, WunschmannS, DiekemaDJ, et al.Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med2001;345:707. CrossRef

434. YeoAE, MatsumotoA, HisadaM, et al.Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med2000;132:959. CrossRef

435. NishizawaT, OkamotoH, KonishiK, et al.A novel DNA virus (TTV) associated with elevated transaminase levels in posttransfusion hepatitis of unknown etiology. Biochem Biophys Res Commun1997;241:92. CrossRef

436. SimmondsP, DavidsonF, LycettC, et al.Detection of a novel DNA virus (TTV) in blood donors and blood products. Lancet1998;352:191. CrossRef

437. MatsumotoA, YeoAE, ShihJW, et al.Transfusion‐associated TT virus infection and its relationship to liver disease. Hepatology1999;30:283. CrossRef

438. TawaraA, AkahaneY, TakahashiM, et al.Transmission of human TT virus of genotype 1a to chimpanzees with fecal supernatant or serum from patients with acute TTV infection. Biochem Biophys Res Commun2000;278:470. CrossRef

439. ShibataM, WangRY, YoshibaM, et al.The presence of a newly identified infectious agent (SEN virus) in patients with liver diseases and in blood donors in Japan. J Infect Dis2001;184:400. CrossRef

440. UmemuraT, YeoAE, SottiniA, et al.SEN virus infection and its relationship to transfusion‐associated hepatitis. Hepatology2001;33:1303. CrossRef

441. DitahI, DitahF, DevakiP, et al.Current epidemiology of hepatitis E virus infection in the United States: low seroprevalence in the National Health and Nutrition Evaluation Survey. Hepatology2014;60:815. CrossRef